Stockholm – September 11, 2026 -- SciBase Holding AB (STO: SCIB) has received an additional order worth roughly $0.6 million, or approximately SEK 5 million, from Castle Biosciences (NASDAQ: CSTL) to accelerate an ongoing clinical study and prepare a second trial under their dermatology collaboration.

Order covers Nevisense Go devices and electrodes for atopic dermatitis research

The order includes both SciBase's portable Nevisense Go pen device and associated electrodes. Deliveries are scheduled to begin in the fourth quarter of 2026.